SynthesisBMC neurology2026
A systematic review of risk factors for vascular dementia using Mendelian randomization: a call for methodologically robust studies to advance knowledge.
Synthesis in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundVascular cognitive impairment, of which vascular dementia is the most extreme end of the spectrum, is a result of many risk factors (exposures). Mendelian randomization is a genetic epidemiological approach to assess the causal relationship between a genetically predicted exposure with an outcome of interest that has gained traction in recent years in part due to the emergence of biobank-scale datasets.
methodsHere, we performed a systematic review of published Mendelian randomization studies to understand the current knowledge of potentially causal genetically predicted exposures on vascular cognitive impairment or vascular dementia risk.
resultsNo results were obtained for vascular cognitive impairment. 26 of the 53 of the articles (49%) identified in our review for vascular dementia found evidence using Mendelian randomization for a causal relationship between a genetically predicted exposure and vascular dementia. Among the studies that investigated similar exposures, some consistently yielded positive causal results between certain types of genetically predicted exposures (e.g. predicted markers of inflammation or atherosclerotic vascular disease) and vascular dementia. In contrast, the presence of a causal effect between certain exposures (e.g. cholesterol levels) and vascular dementia was inconsistent depending on the study. Only 10 of the 26 articles (38%) suggesting a causal link included a completed STROBE-MR checklist, warranting caution in interpretation of results.
conclusionsFrom our systematic review, we identified evidence of potential causal effects between genetically predicted exposures, such as atrial fibrillation, major depressive disorder and gut microbiota, on vascular dementia risk, some of which are supported by multiple studies whereas others require replication. We strongly encourage future Mendelian randomization studies to follow and report the appropriate checklist (STROBE-MR) to employ triangulation and to include individuals of diverse genetic ancestries to allow for more robust exposures on vascular dementia risk for follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.